Clinical trials: Eye
Non-infectious Anterior Uveitis
A Phase 3 Study of VVN461 Ophthalmic Solution for Noninfectious Anterior Uveitis
This is a multicenter, randomized, single-masked, active-controlled, parallel, Phase III pivotal study in China
- Trial name
- NCT07136805
- Testing
- VVN461 Ophthalmic Solution 1.0%, 1.0% prednisolone acetate
- Where
- 2 sites in China
- Volunteers
- 154 people
- Sponsor
- VivaVision Biotech, Inc
Thyroid Eye Disease (TED), Graves' Disease
Evaluation of ETHY-001 for Safety, Tolerability, and Clinical Activity in Thyroid Eye Disease
The primary objective of study is to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ETHY-001 in healthy volunteers and participants with Thyroid Eye Disease after single subcutaneous doses.
- Conditions
- Thyroid Eye Disease (TED), Graves' Disease, Eye Diseases, Hereditary, Eye Diseases
- Trial name
- NCT07885605
- Testing
- ETHY-001
- Where
- 3 sites in United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Ethyreal Bio, Inc.
Choroidal Neovascularization, Wet Macular Degeneration
Open-Label Study of Intravitreal ICON-1 in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration (AMD)
The purpose of this study is to evaluate the safety and effects of repeated intravitreal injections of ICON-1 0.6 mg administered as maintenance therapy or in combination with aflibercept in patients with wet macular degeneration.
- Trial name
- DECO (NCT03452527)
- Testing
- ICON-1, aflibercept
- Where
- 8 sites in United States
- Volunteers
- 15 people
- Sponsor
- Iconic Therapeutics, Inc.
Age Related Macular Degeneration (AMD)
ORACLE: A Long-term Follow-up Study to Evaluate the Safety of GT005 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration Treated in a Gyroscope-sponsored Antecedent Study
The purpose of this study is to evaluate the long-term safety of GT005 in participants with Geographic Atrophy (GA) secondary to AMD who have been treated in an antecedent study.
- Trial name
- ORACLE (NCT05481827)
- Testing
- GT005
- Where
- 32 sites in United States, Australia and 4 more
- Volunteers
- 225 people
- Sponsor
- Gyroscope Therapeutics Limited
Cataract
Study of T-PRED(TM) Compared to Pred Forte(R) II
Study of T-PRED(TM) Compared to Pred Forte(R)
- Trial name
- NCT00854061
- Testing
- T-Pred, Pred Forte
- Where
- United States
- Volunteers
- 172 people
- Sponsor
- Bausch & Lomb Incorporated
Myopia, Ametropia
Clinical Evaluation of the Safety and Efficacy of a New Multifocal Contact Lens
The purpose of this study was to demonstrate substantial equivalence of the new DAILIES® AquaComfort Plus® Multifocal (DACP MF) contact lens to the commercially available Focus® DAILIES® Progressives (FDP) contact lens.
- Conditions
- Myopia, Ametropia, Presbyopia, Refractive Error
- Trial name
- NCT01797783
- Testing
- Nelfilcon A multifocal contact lens with comfort additive, Nelfilcon A multifocal contact lens
- Volunteers
- 83 people
- Sponsor
- Alcon Research
Astigmatism, Myopia
Evaluation of Two Daily Disposable Contact Lenses for Wearers With Astigmatism
The purpose of this trial is to compare the performance of two contact lenses for contact lens wearers with astigmatism.
- Trial name
- NCT01207466
- Testing
- Nelfilcon A investigational contact lens, Nelfilcon A commercial contact lens
- Volunteers
- 95 people
- Sponsor
- CIBA VISION
Dry Eye
A Clinical Trial to Assess Subjects With Dry Eye Disease.
A Multi-Center Randomized, Double-Masked, Parallel Design, Vehicle-Controlled Phase 2 Clinical Trial to Assess the Efficacy and Safety of 0.25% Reproxalap Ophthalmic Solution Compared to Vehicle in Subjects with Dry Eye Disease
- Trial name
- NCT04971031
- Testing
- Reproxalap Ophthalmic Solution (0.25%), Vehicle Ophthalmic Solution
- Where
- United States
- Volunteers
- 158 people
- Sponsor
- Aldeyra Therapeutics, Inc.
Dry Age-related Macular Degeneration, Geographic Atrophy
Investigating Geographic Atrophy Insights (i-GAIN) Natural History Study
An observational study to investigate the natural history and evaluate biomarkers of participants with geographic atrophy secondary to age-related macular degeneration
- Conditions
- Dry Age-related Macular Degeneration, Geographic Atrophy, Retinal Disease, Macular Degeneration
- Trial name
- i-GAIN (NCT05797896)
- Where
- 22 sites in United States, United Kingdom
- Volunteers
- 234 people
- Sponsor
- Complement Therapeutics
Glaucoma, Open-Angle, Ocular Hypertension
Study Comparing Quantitative Assessments in Open-angle Glaucoma (OAG) and/or Ocular Hypertension (OHT)
This study will evaluate assessments from the Goniometric Lens compared with those from anterior segment imaging in patients with open-angle glaucoma (OAG) and/or ocular hypertension (OHT).
- Trial name
- NCT01540370
- Testing
- No Treatment
- Where
- United States
- Volunteers
- 102 people
- Sponsor
- Allergan
Acute Viral Conjunctivitis
FST-100 in the Treatment of Acute Viral Conjunctivitis
This randomized, double masked, multi-center study is being conducted to support the safety and efficacy of FST-100 for the treatment of acute viral conjunctivitis.
- Trial name
- NCT01461954
- Testing
- FST-100, FST-100 Vehicle
- Where
- 2 sites in United States, Brazil
- Volunteers
- 132 people
- Sponsor
- Shire
Pain, Inflammation
Efficacy Study of Bromfenac Ophthalmic Solution in Patients Undergoing Cataract Surgery
Efficacy study of Bromfenac Ophthalmic Solution in cataract surgery
- Trial name
- NCT00853970
- Testing
- Bromfenac Ophthalmic Solution
- Where
- United States
- Volunteers
- 299 people
- Sponsor
- Bausch & Lomb Incorporated
Dry Eye
Evaluating a Device for Blocking the Tear Duct
Participants will receive a tear duct plug to see if their eye comfort improves.
- Trial name
- NCT05748951
- Testing
- Canalicular occlusion device
- Where
- Mexico
- Volunteers
- 33 people
- Sponsor
- AesculaTech, Inc.
Glaucoma
Evaluating the Efficacy and Safety of Xalost S in Glaucoma Patients.
In patients with Glaucoma, Xalost S or Xalatan or Taflotan-S are administered for 12 weeks. After 12 weeks, among them, Xalatan administration group are switched to Xalost S or Taflotan-S. Extension study period is 8 weeks.
- Trial name
- NCT04164459
- Testing
- Xalost S, Xalatan, Taflotan-S
- Where
- South Korea
- Volunteers
- 144 people
- Sponsor
- Taejoon Pharmaceutical Co., Ltd.
Glaucoma, Ocular Hypertension
A Safety and Efficacy Study of ALPHAGAN® P and LUMIGAN® in Subjects Previously Treated With Latanoprost for Glaucoma and Ocular Hypertension
This study will evaluate the efficacy and safety of either bimatoprost 0.01% ophthalmic solution (Lumigan®) alone or bimatoprost 0.01% ophthalmic solution (Lumigan®) and brimonidine tartrate 0.1% ophthalmic solution (Alphagan® P)…
- Trial name
- NCT01525173
- Testing
- 0.1% brimonidine tartrate ophthalmic solution, 0.01% bimatoprost ophthalmic solution, 0.2% hypromellose lubricant eye drops
- Where
- United States
- Volunteers
- 137 people
- Sponsor
- Allergan
Cataracts
Dispervise Ophthalmic Viscoelastic as an Agent to Ensure Watertight Wound Closure After Clear Corneal Cataract Incisions
The purpose of this study is to look at the ability of Viscoat to ensure proper wound closure.
- Trial name
- NCT01298973
- Testing
- Viscoat, Saline
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- Innovative Medical
Cataract Senile
Precisight® Intraocular Lens Implantation for Cataract Treatment
The purpose of this study is to determine the refractive outcomes and optimize the clinical features of a new intraocular lens intended to treat the senile cataract.
- Trial name
- PEACE (NCT02970487)
- Testing
- Intraocular implant of the Precisight
- Where
- Philippines
- Volunteers
- 96 people
- Sponsor
- InfiniteVision Optics
Thyroid Eye Disease
A Safety, Tolerability and Pharmacokinetics Study of VRDN-003 in Participants With Thyroid Eye Disease (TED)
This is a clinical trial assessing the safety, tolerability and pharmacokinetics (PK) of an investigational drug, VRDN-003, in participants with TED (Thyroid Eye Disease)
- Trial name
- NCT07155668
- Testing
- VRDN-003, Autoinjector
- Where
- 13 sites in United States
- Volunteers
- 87 people
- Sponsor
- Viridian Therapeutics, Inc.
Wrinkle, Photoaging
An Open-Label Clinical Study to Evaluate the Efficacy of a Face Cream and Eye Cream
This single-center clinical trial is being conducted to assess the efficacy and tolerability of an anti-aging eye cream and face moisturizer when used over the course of 12 weeks twice-daily by women, 35-65 years, with mild to…
- Conditions
- Wrinkle, Photoaging, Fine Lines
- Trial name
- NCT04911374
- Testing
- Gentle Cleansing Lotion, Revision Skincare, Aveeno Face Milk SPF 40+
- Where
- United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Revision Skincare
Meibomian Gland Dysfunction (Disorder)
TearCare MGX™ System With and Without Warming Hold
TearCare is an office-based thermal therapeutic eyelid technology cleared by the US Food and Drug Administration for the treatment of evaporative dry eye disease due to meibomian gland dysfunction.
- Trial name
- XTEND (NCT07365735)
- Testing
- localized heat therapy
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Sight Sciences, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.